Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (18 ops.)
Latest filing published 01 Aug 2023 for CNS Pharmaceuticals, Inc., €13k.
Filing timeline
BuySaleWaldemar Priebe
Insider track record
Disclosed buys
0
Disclosed sells
18
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Waldemar Priebe: trading record in brief
Waldemar Priebe (chief executive) discloses dealings in 2 companies, chiefly CNS Pharmaceuticals, Inc. and Moleculin Biotech, Inc. We count 19 filings; the first trade dates from 16 August 2017 and the latest from 28 March 2023.
On the market, this insider has only sold: 18 sales, €269k in total. 2023 to date brings no purchases and 17 sales.
The latest filing, published on 1 August 2023, reports an open-market sale of €9,595 in CNS Pharmaceuticals, Inc. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Waldemar Priebe
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations2 total
5,500 shares@ US$2.47100.0% of flowCommon StockSEC:0000897069-23-001044:0
1,495,867 sharesCommon StockSEC:0001683168-22-000460:0
2 of 2 declarations
